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Abstract
Bariatric surgery has become an established evidence-based treatment option for diabetes associated with
obesity. Numerous studies have demonstrated that bariatric surgery is superior to conventional medical treatment
and is effective in achieving resolution of hyperglycaemia or improvement in glycaemic control in type 2 diabetes.
However, diabetes remission after bariatric surgery does not occur universally in patients and surgical procedures
are associated with the risks of complications. It is imperative to identify patients who are likely to gain the best
possible metabolic benefit i.e. resolution of diabetes from bariatric surgery. Several clinical and biochemical factors
have been studied to predict diabetes remission following bariatric surgery. This article provides a concise review
within this area and describes the available scoring systems to predict diabetes remission.
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Introduction
In 2008, the World Health Organisation described that 1.4 billion
people were overweight and more than 0.5 billion were obese. These
figures are estimated to rise to 2.3 billion and 0.7 billion by 2015 [1]. At
least 2.8 million people die each year as a consequence of obesity
related mortality [1]. Obesity is strongly associated with diabetes,
cardiovascular diseases and cancers.
Globally, 44% of diabetes, 23% of ischaemic heart disease and 7-41%
of cancers are attributable to being overweight and obesity [1]. In the
United Kingdom (UK) in 2012, 62% of adults were overweight, with
25% being obese [2]. The UK prevalence of diabetes in adults was 6%
in 2013 [3] and 90% of adults with type 2 diabetes (T2DM) are
overweight or obese. The parallel rise in the prevalence of both obesity
and T2DM has become a major health problem.
Metabolic (bariatric) surgery has become an established evidence-
based treatment option for obesity related T2DM. International and
national guidelines support this therapeutic approach for people with
T2DM and a body mass index (BMI) ≥ 35 kg/m2. Bariatric surgical
procedures include laparoscopic adjustable gastric banding (LAGB),
Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), bilio-
pancreatic diversion (BPD) and duodenal switch (DS). Numerous
studies have shown that bariatric surgery is superior to conventional
medical treatment, and moreover is effective in achieving remission of
T2DM [4,5]. However, the resolution of T2DM following metabolic
surgery is not universal.
The Swedish Obese Subjects Study data showed that the remission
of diabetes was 72% at 2 years and 36% at 10 years [4]. The second
National Bariatric Surgery Register (NBSR) report showed an 80%
remission at 3 years following bariatric surgery [5]. In addition, whilst
bariatric surgery is associated with a low morbidity and mortality [5],
all the surgical interventions except LAGB are generally accepted to be
irreversible, invasive and carry risks.
Controversy and lack of clarity exists within published data relating
to the preoperative clinical or biochemical measurements which might
predict T2DM resolution [6]. A robust prediction model might
support the bariatric multidisciplinary team in identifying the most
suitable patient for surgery and the appropriate surgical procedure.
Within the UK and other parts of the world, metabolic surgery remains
rationed as a consequence of funding difficulties, lack of experienced
staff and other challenges, and therefore a clinical tool to predict
diabetes outcome is desirable.
Factors Predicting Remission of Type 2 Diabetes
Following Bariatric Surgery
Several clinical and biochemical factors have been proposed as
predictors of T2DM resolution after weight loss surgery, as
summarised in Table 1.
Clinical predictors Biochemical predictors
Age
BMI
Duration of T2DM
Severity of T2DM
Glycaemic control: Fasting blood
glucose and HbA1c
C-peptide level
BMI: body mass index; T2DM; type 2 diabetes
Table 1: Pre-operative predictors of diabetes remission after bariatric
surgery
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Clinical predictors
1. Age: Age is an important consideration in patient selection for
bariatric surgery [7]. Increasing age is not only associated with higher
perioperative and postoperative complications but is also less
successful with respect to weight loss [8,9]. Previous studies have
shown that younger age is associated with both early and late
remission of T2DM following surgery [10-13]. However, this may be
debatable [7]. Still et al., studied 690 patients and observed that each
10-year decrease in age was associated with a greater odds ratio (OR)
of early (1.41 [1.10-1.80], p=0.0071) and later remission of T2DM
(1.45 [1.10-1.92], p=0.0085) [14]. Hamza et al., also observed that
younger age was an independent predictor of postoperative T2DM
remission [13]. Similar findings have also been observed by Huang et
al., in a study of 22 Chinese patients with a BMI between 25-35 kg/m2
[12]. Furthermore, a German study found that increasing age was an
independent significant predictor for postoperative metabolic failure
[10]. These observations were confirmed by a recently published meta-
analysis of 13 studies (n=1149) which showed a significant negative
association between preoperative age and T2DM remission (OR: -2.46
[-3.90 to -1.02], p< 0.01) [15].
2. Body Mass Index: Visceral obesity has a strong association with
insulin resistance and T2DM [16] and hence weight loss improves
insulin sensitivity and T2DM. However, it is now evident from the
published literature that improvements in insulin and glucose
homeostasis are observed soon after SG, RYGB and BPD. Therefore it
may be argued that improved glycaemic control occurs before
significant weight loss. Several explanations have been provided for
this phenomenon including effects on the incretin response, changes in
ghrelin and other gut hormones and improved hepatic insulin
sensitivity [17]. Furthermore significant early changes have been
observed in adipose related cytokines such as interleukin-6, leptin and
C-reactive protein, all of which have effects to induce insulin resistance
[18]. However, we cannot generalise that obesity and T2DM always
occur together. Clearly not all people with T2DM are obese and not all
obese people have T2DM [2]. T2DM is a complex heterogeneous
condition with differing pathophysiological contributions from insulin
resistance, excess hepatic glucose release and pancreatic beta cell
dysfunction [19]. Therefore, individuals with increased susceptibility
to develop T2DM at a lower BMI might produce less insulin or might
become insulin resistant with only minimal weight gain. The majority
of the current guidelines recommend bariatric surgery in white-
caucasian individuals with BMI ≥35 kg/m2 and T2DM [20,21]. The
most recent NICE guideline recommend that assessment for bariatric
surgery for South Asian individuals should be at a lower BMI than
other populations [20].
Several studies have found a higher preoperative BMI is associated
with better T2DM resolution following surgery. Of interest, DiGiorgi et
al., found that patients with a re-occurrence of T2DM or a
deterioration in glycaemic control following surgery was associated
with a lower baseline BMI (47.9 v 52.9 kg/m2, p=0.05) [22]. Similar
findings have been observed in Asian samples [11,23]. Dixon et al.
observed that patients with a preoperative BMI >35 kg/m2 had higher
rate of diabetes remission compared to those with a BMI <35 kg/m2
[11]. Furthermore, in a Chinese study of subjects with T2DM and a
BMI <30 kg/m2, the glycaemic response to RYGB was predicted by
higher baseline BMI [23]. Interestingly, in a recently published meta-
analysis, waist circumference rather than BMI was the only significant
predictor [24]. Panunzi et al., observed similar T2DM remission in two
groups with a BMI <35 kg/m2 and a BMI >35 kg/m2 [24]. Other
studies found that a super-obese BMI was not a good predictor of
T2DM resolution [25] and may be associated with reduced life
expectancy [26]. Robert et al., showed that a baseline BMI <50 kg/m2
had 70% sensitivity and 80% specificity (p=0.001) to predict T2DM at
one year [27]. A recently published study found that bariatric surgery
may reduce life expectancy in an individual with diabetes with BMI >
62 kg/m2 [26].
3. Duration of Diabetes: Progressive pancreatic beta cell failure is a
typical feature of T2DM and progresses with diabetes duration [19].
The remission of T2DM following bariatric surgery is dependent on
beta cell function to synthesise and release insulin [28]. Furthermore, a
substantial proportion of individuals may have asymptomatic or
undiagnosed T2DM, or impaired glucose tolerance for many years
prior to diagnosis. This is supported by the International Diabetes
Federation (IDF) estimate that 175 million people worldwide have
undiagnosed diabetes [29]. This will therefore lead to challenges in
reliably knowing the duration of T2DM. Within the available literature,
the duration of diabetes is consistently described as a prognostic factor
for T2DM remission. However, there appears to be little consensus in
relation to cut-off value for the duration of diabetes. Most studies
recommend a cut-off value of between 4-8 years as an independent
prognostic value for diabetes remission [9-11,23,27,30]. Pories et al.,
observed that patients with good metabolic response had a shorter
duration of diabetes (1.75 ± 0.69 vs. 8.79 ± 2.8 years) [9]. Schauer et al.,
replicated similar findings and showed that patients with a diabetes
duration <5 years had a greater chance of complete remission after
gastric bypass surgery [30]. Robert et al., demonstrated that a duration
<4 years had a 79% sensitivity and 80% specificity (p=0.0001) to
predict resolution at one year [27]. In a study by Casella et al., a 10-
year cut-off in diabetes duration yielded a 75% sensitivity and 96%
specificity for diabetes remission after SG [31]. Of interest, within the
UK, the most recent NICE guidance on obesity has been updated so
that consideration of bariatric surgery should be made in patients with
recently diagnosed diabetes and BMI between 30-35 kg/m2 [20].
4. Severity of Type 2 Diabetes: As described previously, the
remission of T2DM depends on the degree of beta cell dysfunction and
duration of diabetes. The requirement of diabetes medications to
control hyperglycaemia might therefore reflect on the severity of
T2DM. Different guidelines recommend different treatment
algorithms and some recommend early insulin use [21,32]. The
duration of undiagnosed diabetes will also necessitate more rapid
progression to insulin therapy. The initiation of insulin treatment in
T2DM typically occurs when there is failure of oral therapies. This
failure is the result of beta cell exhaustion so that the oral agents are no
longer effective in promoting insulin release [19]. In the DiaRem Score
study, the use of insulin therapy prior to surgery is one of four
variables predicting diabetes remission. This showed that 90.1% (95%
CI: 86.6-93.6%) of patients who had not been on insulin prior to
surgery had achieved remission after 5 years, compared with 31.1%
(23.5-38.6%) of those receiving insulin [14]. Robert et al., also
demonstrated that non-insulin based therapies was an independent
predictor for remission one year after surgery (AUC ROC 0.858,
p=0.0001, sensitivity 96% and specificity 60%) [27]. Similarly,
Blackstone et al., observed that the remission rates were greater for 505
patients not using insulin pre-operatively (53.8% v 13.5%, p<0.001)
[33]. In a study of 130 subjects, 100% of patients who had previously
unrecognised diabetes or diet control T2DM achieved remission after
one year, compared with 93% of those on oral hypoglycaemic agents
and 50% of those receiving insulin [34].
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Biochemical predictors
1. Glycaemic control prior to metabolic surgery: Fasting blood
glucose and HbA1c: Chronic hyperglycaemia has a detrimental effect
on pancreatic beta cell function and number. Glucotoxicity leads to
beta cell apoptosis, subsequent insulin hyposecretion, elevated blood
glucose levels and finally further progressive beta cell decline [35].
Therefore the beta cells become desensitised, exhausted and apoptotic.
With the normalisation of blood glucose level, beta cells recovery is a
possibility [36] and hence good glycaemic control results in a higher
probability of beta cell recovery. Lower plasma levels of fasting blood
glucose and HbA1c are associated with a greater probability of T2DM
remission following surgery. In a study of 127 patients with T2DM,
Hayes et al., [34] showed that lower levels of fasting blood glucose and
HbA1c were markers for T2DM remission after gastric bypass surgery.
The strongest negative predictor was a high HbA1c and requirement of
insulin treatment. Similarly, Robert et al., [27] concluded that a fasting
glucose <114mg/dL and a HbA1c <7.1% were predictors for T2DM
resolution at one year, regardless of the type of bariatric operations. In
a study by Jurowich et al. [10], 17 out of 82 participants did not show
an improvement in their diabetes with non responders having a higher
preoperative HbA1c level (8.34% vs. 7.78%, p=0.033). In the DiaRem
score [14] preoperative HbA1c was one of four scoring criteria. Higher
HbA1c level was associated with a higher hazard ratio for persisting
diabetes. The hazard ratios for HbA1c ranges 6.5-5.9%, 7-8.9% and
≥9% were 1.46 [1.12-1.89], p=0.0045, 2.51 [1.96-3.23], p<0.0001 and
3.35 [2.24-5.03], p<0.0001 respectively. Short-term (over six months)
glycaemic improvement prior to bariatric surgery has a significant
impact on the metabolic outcome postoperatively. In a study of 245
diabetes patients undergoing RYGB, preoperative tight blood glucose
control resulted in a 58% greater chance of remission [7].
2. C-peptide level: C-peptide is a 31-amino acids peptide, produced
during cleavage of insulin from pro-insulin in the pancreatic beta cells
[37]. C-peptide and insulin are released in equimolar amounts from
pancreatic beta cells into the portal circulation. Both insulin and C-
peptide levels are biologic markers of pancreatic beta cell function, but
C-peptide is a better proxy for estimating beta cell reserve, because of
its longer half-life and renal clearance. Endogenous insulin
concentrations may also be high in obese individuals with insulin
resistance. In addition, measurement of endogenous insulin may be
affected by exogenous insulin and anti-insulin-antibodies especially in
those treated with insulin [38]. Therefore, C-peptide may be a better
surrogate marker for pancreatic beta cell reserve and an index of
endogenous insulin secretion. As already discussed, T2DM is complex
and the pathophysiology is a result of both insulin resistance and beta
cell dysfunction. Remission of T2DM following surgery depends on
the baseline beta cell function. Studies by Dixon et al., demonstrated
that fasting C-peptide measurement preoperatively was a good
predictor in Asian populations [11,23]. A fasting C-peptide>2.9ng/mL,
a diabetes duration <4 years and BMI >35 kg/m2 were independent
predictors for T2DM resolution at 12 months. A similar finding was
observed by Ramos-Levi et al. [39], where pre-operative C-peptide
levels were higher in those achieving remission at one year. C-peptide
measurements also have a role in predicting T2DM resolution at 3
years following bariatric surgery. In a study of 29 participants with
impaired glucose tolerance and 56 with T2DM, 90% of T2DM patients
with a preoperative fasting C-peptide value >1.0nmol/L (3.0ng/mL)
achieved a postoperative HbA1c <6.5% and 74% achieved complete
resolution after 3.6 ±0.16 years follow-up [40]. A meta-analysis of 142
patients with T2DM in two Asian studies showed a significant
association between preoperative C-peptide levels and remission
(OR=0.62 [0.33-0.91], P<0.01) [15].
Scoring systems
Several scoring systems have been developed in an attempt to
predict T2DM remission following metabolic surgery. However, these
scoring systems are not designed for all bariatric surgical procedures
and are not validated across all population. For instance, the DiaRem
score is designed for RYGB [34]; the Indian Diabetes Remission score
is based on a local population [41]; and the ABCD scoring system is
only validated for an Asian population who have a different phenotype
of T2DM (lower BMI) compared to Western populations [42,43].
The DiaRem score
Age (years) Score
<40 0
40-49 1
50-59 2
≥60 3
HbA1c
<6.5% 0
6.5-6.9 2
7-8.9 4
≥9 6
Other diabetes drugs
No SU or Insulin-sensitising agent
other than metformin
0
SU or Insulin-sensitising agent other
than metformin
3
Treatment with insulin
No 0
Yes 10
SU: sulphonylurea
A lower DiaRem score is associated with a greater likelihood of diabetes
remission following RYGB surgery
Table 2: The DiaRem Score [34]
Still and colleagues have described this scoring system to predict
probability of diabetes remission following RYGB [14]. The scoring
system consists of four preoperative clinical variables: age, HbA1c,
insulin use, and type of diabetes medications (Table 2). The score
ranges from 0-22, with the greatest emphasis being on insulin use
preoperatively. A lower DiaRem score is associated with a greater
likelihood of diabetes remission following RYGB surgery. Within the
study, 88% of patients who scored 0-2 achieved diabetes remission,
whilst 2% of those who scored 18-22 did. Of note, they also observed
that preoperative use of incretin mimetic improved the likelihood of
diabetes remission postoperatively.
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The ABCD Diabetes Surgery score
Lee et al., proposed a scoring system comprising of age, BMI, C-
peptide and duration of diabetes. The initial score was designed for
RYGB surgery (Table 3) [43] and then modified for SG (Table 4) [42].
The Diabetes Surgery score for RYGB was validated in 176 Asian
patients [43].
Variables Diabetes Surgery Score
0 1 2 3
Age ≥40 <40
BMI <30 30-39 40-49 >50
C-peptide (ng/mL) 0.9-1.9 2.0-3.9 4-6 >6
Duration of diabetes >10 5-10 2-4.9 <2
RYGB: Roux-en-Y gastric bypass; BMI: body mass index
Table 3: Diabetes Surgery Score (RYGB) [43]
Remission of T2DM was defined as a fasting blood glucose <110
mg/dL and HbA1c <6% without the use of anti diabetic drugs or
insulin. A total of 115 remissions (65.3%) were observed one year after
RYGB. Patients with T2DM remission after surgery had a greater
Diabetes Surgery Score than those without (8 ± 4 vs. 4 ± 4, p<0.05).
Patients with a greater Diabetes Surgery Score also had a greater rate of
success of T2DM remission (from 33% at score 0 to 100% at score ≥8).
Variables Diabetes Surgery Score
0 1 2 3
Age ≥40 <40
BMI <27 27-34.9 35-41.9 >42
C-peptide (ng/mL) <2 2.0-2.9 3-4.9 >5
Duration of diabetes >8 4-8 1-3.9 <1
LSG: laparoscopic sleeve gastrectomy; BMI: body mass index
A higher Diabetes Surgery score is associated with a greater likelihood of
diabetes remission following bariatric surgery
Table 4: Diabetes Surgery Score (LSG) [42]
A 1-point increment in the Diabetes Surgery Score translated to an
absolute 6.7% in the success rate. The modified ABCD Diabetes
Surgery Score was validated in 85 Asian patients undergoing LSG [42].
At 12 months following LSG, 52.9% had complete remission (HbA1c
<6.0%) and 21.2% had partial remission (HbA1c <6.5%). Responders
had a higher ABCD score than non-responders (7.3 ± 1.7 vs. 5.2 ± 2.1,
p<0.05). Patients with a higher ABCD score also had higher T2DM
remission (0% in score 0 to 100% in score 10).
The Diabetes Remission Score
An Indian study [41] reported a Diabetes Remission Score (DRS)
for two bariatric surgical procedures: Ileal Interposition coupled with
Sleeve Gastrectomy (IISG) (n=46) and Diverted Sleeve Gastrectomy
(IIDSG) (n=29) (Table 5). The scoring system used 7 parameters: age,
BMI, duration of diabetes, microvascular complications,
macrovascular complications, preoperative insulin use, and stimulated
C-peptide. They concluded that the score was significantly lower in
patients with remission than those without remission. Patients with a
DRS ≥ 10 in IISG group and more than 12 in IIDSG group did not get
into remission.
Parameters Diabetes Remission Score
1 2
Age (years) 30-60 <30 or >60
BMI ≥27 <27
Duration of diabetes <10 >10
Microvascular complications No Yes
Macrovascular complications No Yes
Preoperative insulin use No Yes
Stimulated C-peptide ≥4 <4
BMI: body mass index
A lower Diabetes remission score is associated with a greater chance of
diabetes remission following bariatric surgery
Table 5: Diabetes Remission Score [41]
Conclusion
Bariatric surgery is an effective treatment option for obesity
associated T2DM. Patient selection is important to optimise maximal
benefit with minimal adverse outcomes. Preoperative clinical and
biochemical factors that could predict the outcome of T2DM following
bariatric surgery would be useful for the bariatric multidisciplinary
team. It may be impossible to identify the most important single
predictor as most of the clinical and biochemical predictive factors
described above are inter-related to one another. For example a longer
duration of diabetes is associated with increasing age; the need for
insulin therapy is associated with a long duration of diabetes; a long
duration of diabetes and poor glycaemic control is associated with
poor pancreatic beta cell reserve. A simple, but robust diabetes surgery
scoring system that could be applicable to all type of bariatric surgical
procedures and across the population is needed. Furthermore, most of
the studies investigating predictors have examined diabetes resolution
at 12-14 months postoperatively. Further studies investigating longer
term outcome i.e. 5 years and above are needed as well. Furthermore
further investigation is required examining the resolution of T2DM
following surgery in different ethnic groups. Of note there is paucity in
the published literature examining this in Latino and African-
American patients.
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